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Risk Factors and Clinical Outcomes of Head and Neck Cancer in 
Inflammatory Bowel Disease: A Nationwide Cohort Study
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Carla M. van Herpen, PhD,† Wietske Kievit, PhD,‡ Rob Verhoeven, PhD,**  
Esther van den Broek, PhD,†† Elise Bekers, MD,§ Tim van den Heuvel, MSc,‡‡  
Marieke Pierik, PhD,‡‡ Janette Rahamat-Langendoen, PhD,¶ Robert P. Takes, PhD,‖  
Willem J. G. Melchers, PhD,¶ Iris D. Nagtegaal, PhD,§ and Frank Hoentjen, PhD*;  
on behalf of the Dutch Initiative on Crohn and Colitis (ICC), Dutch Head and Neck Society, PALGA group, and 
IBD/HNC group
Background: Immunosuppressed inflammatory bowel disease (IBD) patients are at increased risk to develop extra-intestinal malignancies. 
Immunosuppressed transplant patients show increased incidence of head and neck cancer with impaired survival. This study aims to identify risk 
factors for oral cavity (OCC) and pharyngeal carcinoma (PC) development in IBD, to compare clinical characteristics in IBD with the general 
population, and to assess the influence of immunosuppressive medication on survival.
Methods: We retrospectively searched the Dutch Pathology Database to identify all IBD patients with OCC and PC between 1993 and 2011. 
Two case-control studies were performed: We compared cases with the general IBD population to identify risk factors, and we compared cases 
with non-IBD cancer patients for outcome analyses.
Results: We included 66 IBD patients and 2141 controls with OCC, 31 IBD patients and 1552 controls with PC, and 1800 IBD controls. Age at 
IBD diagnosis was a risk factor for OCC development, Crohn’s disease (CD; odds ratio [OR], 1.04; 95% confidence interval [CI], 1.02–1.07), and 
ulcerative colitis (UC; OR, 1.03; 95% CI, 1.01–1.06). For PC, this applied to UC (OR, 1.05; 95% CI, 1.01–1.06). IBD OCC cases showed impaired 
survival (P = 0.018); in PC, survival was similar. There was no effect of immunosuppression on survival. Human papillomavirus (HPV) testing 
of IBD cases revealed 52.2% (12/23) HPV-positive oropharyngeal carcinomas (OPCs).
Conclusion: This study shows that IBD is associated with impaired OCC survival. Higher age at IBD diagnosis is a risk factor for OCC devel-
opment. We found no influence of immunosuppression on survival; 52.2% of OPC in IBD contained HPV.
Key Words:  inflammatory bowel diseases, head and neck cancer, pharyngeal carcinoma, oral cavity carcinoma, immunosuppressive therapy
INTRODUCTION
Inflammatory bowel disease (IBD) is mainly diagnosed 
in young people and is characterized by chronic relapsing 
intestinal inflammation. The majority of IBD patients need 
long-term treatment with immunosuppressive medication to 
control the disease and prevent complications.1, 2 Furthermore, 
they have an increased risk of developing both intestinal and 
extra-intestinal malignancies (EIMs).3 Immunosuppressive 
therapy can cause DNA damage and decrease immune surveil-
lance, subsequently increasing EIM risk.4–6 Reduced immune 
surveillance of the human papillomavirus (HPV), for example, 
is one of the contributing factors for the increased incidence of 
cervical cancer in patients with immunosuppression.7–10
HPV is associated with head and neck cancers (HNCs) 
as well, suggesting that immunosuppression use in IBD 
patients may also impact HNC risk in these patients. HPV-
associated HNCs primarily occur in the (oro)pharynx of 
young patients11 without a history of excessive exposure to 
alcohol and tobacco12 and account for more than one-half  of 
cancers of the oropharynx in the United States.13 There is an 
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approximately 2- to 4-fold increased risk of cancers of the oral 
cavity and oropharynx in patients infected with high-risk (onco-
genic) HPV types. However, the reported prevalence seems to 
vary between countries. Recent studies on the prevalence in the 
Netherlands show lower prevalence.14–16 In immunosuppressed 
transplant patients, the incidence of HNC is doubled compared 
with the general population.17, 18 The outcome is worse in this 
group of immunosuppressed patients,17, 19 which may be associ-
ated with high-dose immunosuppression.
Conflicting data on HNC risk in IBD are reported. 
Danish historical cohorts show no increased risk for lip, oral 
cavity, and pharyngeal cancer,20, 21 while more recent US data 
show a standardized incidence ratio (SIR) for oral cancer 
of 9.77 (95% confidence interval [CI], 5.14–16.98)22 in IBD 
patients. Various reports advocate regular oral screening.23, 24 
Currently, studies on risk factor for HNC development and 
HNC outcome in IBD patients are lacking. We hypothesized 
a worse outcome for oral cavity cancer (OCC) and pharyngeal 
cancer (PC) in IBD patients treated with immunosuppression 
in comparison with the general population.
In this study, we aimed to (1) identify risk factors in IBD 
patients that contribute to the development of OCC and PC and 
(2) compare the clinical characteristics, outcome, and survival 
of OCC and PC in IBD patients with the general population.
METHODS
Study Design
This study consisted of 2 retrospective case-control stud-
ies. Cases included IBD patients who developed OCC or PC and 
were selected through PALGA. PALGA is the national nation-
wide registry of cyto- and histopathology of the Netherlands.25
Case-Control Study 1 (I)
For the identification of risk factors for the development 
of OCC and PC in IBD patients, we compared IBD cases with 
HNC with IBD controls. Controls were randomly extracted 
from a population-based IBD cohort in the Netherlands (IBD 
South Limburg [IBDSL]).26
Case-Control Study 2 (II)
For the comparison of clinical characteristics and out-
comes of OCC and PC between patients with and without IBD, 
we compared IBD cases with HNC with controls: patients with 
HNC from the general population. Controls were extracted 
from the Eindhoven Cancer Registry (ECR), a part of the 
FIGURE 1. Flowchart case inclusion.
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Netherlands Cancer Registry (NCR). The study was approved 
by the Privacy Commission and Scientific Council of PALGA, 
by the Medical Ethics Review Committee of the Radboudumc, 
Nijmegen, the Netherlands (registration number 2013/211), 
and by the Medical Ethics Review Committee of the IBDSL.
Case Selection
For the identification of all IBD patients with HNC from 
January 1, 1993, until December 31, 2012, in the Netherlands, 
a search was performed in the national pathology database 
PALGA. PALGA has had nationwide coverage since 199125 
and covers all academic and nonacademic Dutch pathology 
laboratories. Search terms for IBD included “ulcerative colitis” 
or “Crohn’s disease” or “indeterminate colitis” or “chronic idi-
opathic inflammatory bowel disease.” These terms were com-
bined with search terms for HNC, including “head - neck” or 
“pharynx” or “mouth” or “oral cavity” or “lip” or “tongue” or 
“tooth” or “tonsil” or “adenoid.”
An initial selection of cases was made based on pathol-
ogy reports. Subsequently, medical charts were investigated for 
definitive inclusion or exclusion. All IBD patients with primary 
OCC and PC were included in this study. For this study, the 
exclusion criteria were OCC and PC in situ, lymphoma, diag-
nosis of IBD >3 months after OCC or PC diagnosis, OCC or 
PC diagnosis before 1993 or after 2012, and no confirmed diag-
nosis of IBD.
Case Control Study 1 (I): IBDSL Cohort Controls
To identify risk factors, we randomly included IBD con-
trols diagnosed in the period 1991–2011 from the (popula-
tion-based) IBDSL cohort.
The IBDSL cohort comprises adult IBD patients who 
were diagnosed between 1991 and 2011 in the South-Limburg 
area of the Netherlands. The South-Limburg region is a well-de-
fined geographic region in the southeast of the Netherlands, with 
borders to Belgium and Germany and narrowly to the rest of 
the Netherlands in the north. Its geographic isolation results in a 
low net migration rate: 2.1 per 1000 inhabitants per year, favor-
ing population research. A recent completeness check showed 
that 93% of all appropriate IBD patients from South-Limburg 
are currently registered in the IBDSL cohort. For detailed infor-
mation on the IBDSL cohort, we refer to the cohort profile.26
One thousand eight hundred patients with an IBD diag-
nosis between 1991 and 2011 were randomly included, similar to 
our previous studies.27–29 We chose an unmatched study design 
as we had a relatively large number of cases. This allowed us 
to adjust for possible confounders and avoid missing potential 
risk factors.
FIGURE 2. Flowchart ECR control (general population) inclusion.
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Case Control Study 2 (II): ECR Controls
For the comparison of  clinical characteristics and out-
come of HNC in IBD with the general population, controls with 
OCC and PC were identified from the ECR. The ECR is man-
aged by the Netherlands Comprehensive Cancer Organisation 
(NCCO) and prospectively has been registering all newly diag-
nosed cancers in the Southeast of  the Netherlands since 1989. 
It covers a region with 2.3 million inhabitants (about 15% of 
the Dutch population), including more than 95% of all can-
cers in this area (http://www.eindhovencancerregistry.nl). The 
search terms used in this registry were C00, C02, C03, C04, 
C05, C06, C09, C10, C11, C12, C13, and C14, according to the 
ICD-0, third edition.30 We included all OPC and PC controls in 
the period from January 1, 1993, to December 31, 2012. In situ 
cancers and lymphomas were excluded.
Data Extraction
Three authors (L.N., L.D., and A.J.) reviewed the medi-
cal charts of IBD cases, which were anonymized, and extracted 
data of both IBD and HNC diagnosis.
TABLE  1: Univariable Comparison of Potential Risk Factors Between IBD Patients With HNC (Cases) and IBDSL 
Controls
Variables IBDSL Oral Cavity Missing P Pharynx Missing P
n = 1800 n = 66 n = 31
Median age at diagnosis, y 39.00 53.50 0/0 <0.01* 45.00 0/0 0.08
Female sex, No. (%) 983 (53.5) 22 (33.3) 0/0 <0.01* 12 (38.7) 0/0 0.10
Smoking (no; only CD patients), No. (%)
 Nonsmoker 253 (37.5) 9 (30.0) 1/122 0.45 0 (0.0) 3/122 <0.01*
 Smoker 345 (51.2) 15 (50.0) 10 (90.9)
 Ex-smoker 76 (11.3) 6 (20.0) 1 (9.1)
Alcohol use (current and past), No. (%) - 46 (69.7) -/5 - 17 (55.9) -/11 -
Primary sclerosing cholangitis, No. (%) 13 (0.7) 1 (1.8) 4/20 0.36 0 (0.0) 10/20 0.10
IBD type, No. (%)
 Ulcerative colitis 1004 (55.8) 34 (52.4) 0/0 0.586 14 (46.7) 0/0 0.79
 Crohn’s disease 796 (44.2) 31 (47.7) 16 (53.3)
Indeterminate colitis, No. (%) 0 (0.0) 1
Ulcerative colitis, No. (%)a
 Proctitis (E1) 243 (24.4) 0 (0.0) 0/10 <0.01* 1 (7.7) 1/10 0.21
 Left-sided colitis (E2) 472 (47.5) 17 (50.0) 7 (53.8)
 Pancolitis (E3) 279 (28.1) 17 (50.0) 5 (38.5)
Crohn’s disease, No. (%)a
 Ileum (L1) 223 (12.4) 5 9(16.1) 0/1 0.26 1 (7.1) 0/1 0.13
 Colon (L2) 183 (10.2) 10 (32.3) 5 (35.7)
 Ileocolonic (L3) 389 (21.6) 16 (51.6) 8 (57.1)
 Upper digestive (L4) (yes) 65 (3.6) 6 (20.0) 1/60 0.04* 3 (23.1) 1/60 0.09
Stricturating (B2) 263 (14.6) 12 (40.0) 1/0 0.43 5 (38.5) 1/0 0.77
Penetrating (B3) 188 (10.4) 9 (30.0) 1/0 0.42 5 (38.5) 1/0 0.21
Medication, No. (%)
 5-aminosalicylates 1605 (89.2) 50 (87.7) 9/13 0.61 18 (81.8) 9/13 0.27
 Steroids 1113 (61.8) 44 (77.2) 9/13 0.03* 16 (72.7) 9/13 0.33
 Thiopurines 717 (39.8) 30 (52.6) 9/17 0.06 10 (45.5) 9/17 0.62
 Methotrexate 95 (5.3) 1 (1.8) 9/10 0.36 0 (0.0) 9/10 0.63
 Cyclosporin 26 (1.4) 3 (5.3) 9/10 0.06 0 (0.0) 9/10 1.00
 Anti-TNF therapy 350 (19.4) 6 (10.5) 9/25 0.08 4 (18.1) 9/25 1.00
IBD-related surgery, No. (%) 1284 (71.7) 43 (65.2) 0/8 0.25 19 (63.3) 1/8 0.32
Median duration of follow-up since IBD 
diagnosis, y
7.00 9.00 0/30 0.01* 11.00 0/30 0.09
Smoking data of IBDSL only avaible for CD patients.
aAccording to the Montreal classification.
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Data that were collected for the IBD cases included sex, 
date of  birth, medical history, alcohol and smoking history, 
height, and weight. IBD variables that were collected: type 
of  IBD based on histopathologic evaluation, date of  IBD 
diagnosis, IBD phenotype (Montreal Classification),31 pres-
ence of  primary sclerosing cholangitis, IBD medication use 
(5-aminosalicylates, corticosteroids, thiopurines, methotrex-
ate, calcineurin inhibitors, and anti-TNF therapy), period of 
therapy use, and number and type of  surgery. IBD diagno-
sis was predicated on a combination of  several criteria: clin-
ical, endoscopic, histological, and radiographic criteria.32 For 
IBD controls from the IBDSL, same variables were collected, 
although alcohol and smoking history were only partially 
available and duration of  immunosuppressive medication was 
not available.
HNC characteristics for cases and controls included 
diagnosis date, location and tumor stage according the TNM 
classification (7th edition), previous HNC or radiation, dif-
ferentiation grade, primary treatment, (local) recurrence, and 
overall survival.
IBD cases were encrypted and anonymously linked to the 
Dutch Cancer Registry database, for reasons of quality control 
and completion of collected HNC data.
HPV Detection and Genotyping
Sample preparation
We isolated DNA from formalin-fixed paraffin-embed-
ded (FFPE) tissue samples (4 µM) with the EZ1 robot (Qiagen, 
Germany, with the DNA tissue kit of Qiagen) according to 
standard procedures (19). We used them for polymerase chain 
reaction (PCR) analysis. We included a negative water control 
with each batch of samples (10).
Immunohistochemistry
For immunostaining, we used an anti-p16 monoclonal 
antibody (clone G 175–405; BD Pharmi ngen, San Diego, CA, 
USA) with a 1:10 dilution. As positive control, we used cer-
vical cancer tissue with high p16 expression. We scored the p16 
immunohistochemistry positive in case there was strong nuclear 
and cytoplasmic staining present in more than 70% of the 
malignant cells. All other p16 immunohistochemistry patterns 
were scored as negative.
HPV-DNA detection and typing
For the broad-spectrum HPV-DNA amplification per-
formance, we used a short PCR fragment assay (HPV SPF10-
LiPA25, version 1; Labo Bio-medical Products B.V., Rijswijk, 
the Netherlands). This assay amplifies a 65-bp fragment of 
the L1 open reading frame of  HPV genotypes.33 For the HPV 
genotyping, we used a cocktail of  9 conservative probes in a 
micro titer hybridization assay, the DNA enzyme immuno-
assay (DEIA). The samples positive for HPV by DEIA were 
subsequently analyzed with the line probe assay (LiPA25) by 
reverse hybridization with type-specific probes (for HPV 6, 11, 
16, 18, 31, 33, 34, 35, 39, 40, 42, 43, 44, 45, 51, 52, 53, 54, 56, 
58, 59, 66, 68/73, 70, and 74). We inspected and interpreted 
the LiPA strips visually following the standardized reference 
guide. Phocine herpesvirus was used as an internal amplifica-
tion control.
Statistics
For case-control studies 1 (I) and 2 (II), we assessed pos-
sible risk factors, HNC characteristics, and outcomes between 
cases and controls with a univariable analyses. We used a X2 test 
or Fisher exact test (if  suitable) to analyze categorical data. We 
used an independent Student t test or Mann-Whitney U test to 
TABLE  2: Final Multivariable Logistic Regression Model After Adjustment for Confounders and Follow-up: 
Independent Risk Factors for HNC Development
Model Variable Coefficient β Odds Ratio (95% CI) P
Oral cavity
Ulcerative colitis, all cases (n = 34) Age at IBD diagnosis 0.03 1.03 (1.01–1.06) <0.01
Ulcerative colitis Male sex 1.03 2.79 (1.08–7.18) 0.03
Sensitivity analysis (n = 26) Age at IBD diagnosis 0.05 1.05 (1.02–1.08) <0.01
Crohn’s disease Age at IBD diagnosis 0.04 1.04 (1.02–1.07) <0.01
All cases (n = 31) Upper digestive (L4) 1.08 1.10 (1.04–1.17) 0.03
Crohn’s disease Age at IBD diagnosis 0.04 1.04 (1.02–1.07) <0.01
Sensitivity analysis (n = 20)
Oropharynx
Ulcerative colitis, all cases (n = 12) Age at IBD diagnosis 0.05 1.05 (1.00–1.09) 0.01
Ulcerative colitis 5-aminosalicylates -4.03 0.02 (0.01–0.09) <0.01
Sensitivity analysis (n = 9)
Crohn’s disease, all cases (n = 12) No risk factors identified
Crohn’s disease Sensitivity analysis (n = 6) No risk factors identified
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analyze continuous data. We included variables with a P value 
of <0.1 in the univariable analyses in a multivariable model.
For case-control study 1 (I), a multivariable logistic regres-
sion model with backward sampling was performed. In this 
model, we adjusted for the follow-up duration (fixed variable). 
We defined follow-up as time since IBD diagnosis until the date 
of HNC diagnosis (for cases) or the end of follow-up or death 
(for controls). We made the model for CD and UC patients for 
the identification of independent risk factors for development 
of HNC. Because use of medication, especially in the distant 
TABLE 3: Univariable Comparison of Oral Cavity Characteristics Between IBD Cases and Controls From the General 
Population With Oral Cavity
Variable IBD Patients ECR Patients Missing, No. P
n = 66 n = 2141 IBD/ECR
Median age at diagnosis, y 60.50 65.00 0/0 0.02 *
Female sex, No. (%) 22 (33.3) 810 (37.8) 0/0 0.26
Tumor location, No. (%)
 Oral cavity 57 (86.4) 1506 (70.3) 0/0 <0.01*
 Lip 9 (13.6) 635 (29.7)
Histology, No. (%)
 SCC 62 (95.4) 2045 (96.5) 1/0 0.50
Differentiation, No. (%)
 Good 6 (12.2) 486 (27.5) 12/373 0.03*
 Moderate 37 (75.5) 1013 (57.3)
 Poor 6 (12.2) 269 (15.2)
Staging, No. (%)
 T stage oral cavitya
  T1 33 (60.0) 619 (42.0) 2/31 0.07
  T2 12 (21.8) 401 (27.2)
  T3 3 (5.5) 115 (7.8)
  T4 7 (12.7) 340 (23.1)
 N stage oral cavitya
  N0 39 (74.2) 1270 (71.7) 2/80 0.87
  N1 7 (11.3) 184 (10.4)
  N2 9 (14.5) 300 (16.9)
  N3 0 (0.0) 17 (1.0)
 M stage (yes) oral cavitya 1 (1.8) 17 (1.2) 1/121 0.51
TNM – stadium oral cavity, No. (%)
 Stadium I 27 (50.9) 454 (33.8) 4/162 0.05
 Stadium II 7 (13.2) 231 (17.2)
 Stadium III 7 (13.2) 162 (12.1)
 Stadium IV 12 (22.6) 497 (37.0)
TNM – stadium lip, No. (%)a
 Stadium I 7 (100.0) 248 (87.3) 2/351 1.00
 Stadium II 0 (0.0) 20 (7.0)
 Stadium III 0 (0.0) 8 (2.8)
 Stadium IV 0 (0.0) 8 (2.8)
Treatment, No. (%)
 Surgery (yes) 60 (90.9) 1834 (85.7) 0/0 0.23
 Chemo (yes) 1 (1.5) 69 (3.2) 0/0 0.44
 Radiotherapy (yes) 23 (34.8) 750 (35.0) 0/0 0.98
Previous malignancy, No. (%) 14 (21.2) 460 (21.5) 0/0 0.96
Abbreviations: OSCC, oral squamous cell carcinoma; SCC = squamous cell carcinoma.
aAccording to the 7th TNM edition.
Downloaded from https://academic.oup.com/ibdjournal/advance-article-abstract/doi/10.1093/ibd/izy096/4999944
by University of Connecticut user
on 19 May 2018
Inflamm Bowel Dis • Volume 00, Number 00, Month 2018 
7
Head and Neck Cancer in IBD
past, may not be reliable and may differ from current treatment 
regimes, we did not include use of medication in the primary 
multivariable analysis. Therefore, we performed a second multi-
variable logistic regression analysis (which we called sensitivity 
analysis). These analyses included patients with an IBD diagno-
sis since 1991 in both the case and control groups. Medication 
use was included in this second logistic regression model.
For case-control study 2 (II), Kaplan-Meier survival 
curves were made, and we performed log-rank analysis. 
Subsequently, we performed confounder correction with a 
Cox regression model with forward sampling. We considered 
a covariate a confounder when the beta coefficient of  the var-
iable changed by 10% or more. As the clinical behavior (and 
TNM classification) is different for PC subsites (oro-, naso-, 
and hypopharynx), TNM stage and survival were analyzed 
separately.
We considered a P value of <0.05 statistically significant. 
All statistical analyses were performed with IBM SPSS statis-
tics, version 20.0 (SPSS Inc, Chicago, IL, USA).
RESULTS
Cases and Controls
The initial PALGA search yielded 760 IBD and can-
cer cases. First, we excluded 466 patients who did not present 
with either an OCC or a PC (Fig. 1). Second, 197 patients were 
excluded who did not have confirmed IBD in their medical 
records, resulting in 31 patients with PC and 66 with OCC.
For case-control study I, 1800 IBD controls were ran-
domly selected from the IBDSL. For case-control study II, we 
included 2141 patients with OCC and 1552 with a PC from the 
ECR (Fig. 2).
Case Control Study I: Risk Factors for OCC and PC 
Development in IBD Patients
OCC
The univariable comparison between IBD cases and 
IBDSL controls (Table 1) showed that cases were older at IBD 
diagnosis (median 53.5 vs 39.0 years; P < 0.01) and were more 
frequently male (66.7% vs 46.5%; P  <  0.01). UC cases had 
more extensive disease (Montreal E3 disease: 50.0% vs 28.1%; 
P < 0.01), and CD patients had more frequent Montreal L4 dis-
ease (20.0% vs 3.6%; P = 0.037). IBD cases used more steroids 
compared with IBDSL controls (77.2% vs 66.8%; P = 0.03). We 
found no statistical difference in use of thiopurines (cases 52.6 
% vs controls 39.8%; P = 0.06) and anti-TNF therapy (cases 
10.5% vs controls 19.4%; P = 0.08).
In the multivariable logistic regression model, age at IBD 
diagnosis remained an independent risk factor to develop OCC 
in both UC (OR, 1.03; 95% CI, 1.01–1.06) and CD (OR, 1.04; 
95% CI, 1.02–1.07) (Table  2). For CD, Montreal L4 disease 
(OR, 1.10; 95% CI, 1.04–1.17) was an additional risk factor.
PC
We included 31 IBD cases with PC: 25 with oropharyn-
geal carcinoma (OPC) and 6 with hypopharyngeal carcinoma 
(HPC) (Fig.  1). The univariable comparison between cases 
and IBDSL controls only showed a difference in tobacco use 
in CD patients (100% vs 62.5%; P < 0.01). We found no differ-
ences in use of  medication: thiopurines P = 0.62 (cases 45.5% 
vs controls 39.8%) and anti-TNF P  =  1.00 (cases 18.1% vs 
controls 19.4%).
In the multivariable logistic regression model (Table 2), 
no risk factors remained for CD. For UC, age at IBD diagnoses 
was an independent risk factor (OR, 1.05; 95% CI, 1.08–1.06).
The sensitivity analysis revealed a protective effect of 
5-aminosalicylates for OPC in UC patients (OR, 0.02; 95% CI, 
0.01–0.09) (Table 2).
Case-Control Study II: OCC and PC Cases vs ECR 
Controls
OCC
 IBD cases had a lower median age at OCC diagnosis 
(60.5 vs 65.0 years; P = 0.02) compared with controls (Table 3). 
OCC cases had less frequent well-differentiated tumors (12.2% 
vs 27.5%; P = 0.03), and there was a trend toward a lower TNM 
stage (P = 0.05). Overall survival was similar in the univariable 
analysis (P = 0.30) (Supplementary Fig. 1). However, adjusted 
for confounders, IBD cases showed worse survival (P = 0.02) 
(Fig. 3). Immunosuppressive therapy did not negatively affect 
overall survival following OCC (P  =  0.43) (Supplementary 
Fig. 1).
FIGURE 3. Oral cavity malignancy Kaplan-Meier survival curve.
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TABLE 4: Univariable Comparison of Pharynx Carcinoma Characteristics Between IBD Cases and Controls From the 
General Population With Pharynx Carcinoma
Variable IBD Patients ECR Patients Missing, No. P
n = 31 n = 1552 IBD/ECR
Oropharynx and hypopharynx
Median age at diagnosis, y 59.00 61.00 0/0 0.65
Female sex, No. (%) 12 (38.7) 432 (27.8) 0/0 0.22
Tumor location, No. (%)
 Nasopharynx 0 (0.0) 158 (9.4) 0/23 0.09
 Oropharynx 25 (80.6) 1095 (64.9)
 Hypopharynx 6 (19.4) 434 (25.7)
Histology, No. (%)
 SCC 30 (96.8) 1459 (94.0) 1/93 1.00
Differentiation, No. (%)
 Good 2 (9.1) 88 (6.9) 9/275 0.69
 Moderate 11 (50.0) 725 (56.8)
 Poor 9 (40.9) 464 (36.3)
Oropharynx, No. (%)
 T stagea
  T1–T2 18 (75.0) 505 (47.5) 0/33 0.02*
  T3–T4 7 (25.0) 557 (52.5)
 N stagea
  N0 12 (50.0) 363 (34.8) 0/25 0.49
  N1 3 (12.5) 160 (15.3)
  N2 8 (33.3) 469 (45.0)
  N3 1 (4.2) 51 (4.9)
  M stage (yes)a 1 (4.2) 44 (4.4) 1/55 0.96
 TNM – stadium, No. (%)a
  Stadium I –II 9 (37.5) 222 (21.6) 1/65 0.06
  Stadium III–IV 15 (62.5) 808 (78.2)
Hypopharynx
  T stage, No. (%)a
  T1 0 (0.0) 39 (9.3) 1/14 0.51
  T2–T3 4 (80.0) 231 (55.0)
  T4 1 (20.0) 150 (35.7)
 N stage, No. (%)a
  N0 4 (80.0) 109 (26.7) 1/1 0.11
  N1 1 (20.0) 75 (18.3)
  N2 0 (0.0) 188 (46.0)
  N3 0 (0.0) 37 (9.0)
  M stage (yes)a 0 (0.0) 24 (6.0) 1/34 1.00
 TNM – stadium, No. (%)a
  Stadium I 0 (0.0) 11 (2.6) 1/18 0.03*
  Stadium II–III 4 (80.0) 109 (26.2)
  Stadium IV 1 (20.0) 296 (71.2)
Oropharynx and hypopharynx treatment, No. (%)
  Surgery (yes) 14 (46.7) 348 (22.4) 1/0 <0.01*
  Chemo (yes) 2 (6.7) 276 (17.8) 1/0 0.15
  Radiotherapy (yes) 22 (73.3)s 1235 (79.6) 1/0 0.40
Previous malignancy, No. (%) 12 (41.4) 342 (22.0) 2/0 0.01*
Abbreviation: SCC, squamous cell carcinoma.
aAccording to the 7th TNM edition.
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PC
Despite a lower T stage (T1–T2: 75.0% vs 47.5%; 
P  =  0.02) (Table  4) in IBD patients with OPC, comparable 
TNM stage (P  =  0.06) and survival (P  =  0.50) were found 
compared with controls. Immunosuppressive therapy did not 
negatively affect overall survival following OPC (P = 0.10 and 
P = 0.07) (Supplementary Fig. 2A). We found no difference in 
survival between HPV-positive and -negative OPCs (P = 0.45).
IBD patients with HPC (n = 6) had a lower TNM stage 
(P = 0.03) (Table 4) and better overall survival compared with 
the general population (P = 0.01) (Supplementary Fig. 2B).
Both OPC and HPC cases underwent surgery more fre-
quently (46.7% vs 22.4%; P < 0.01) (Table 4).
Histopathology and HPV Analysis
We obtained tissue from 48 of 66 identified OCC cases 
for further analyses. All cases were squamous cell carcinomas, 
and 5 of 48 tumors (10.4%) were p16 positive, suggesting the 
possibility of HPV-related cancers. Subsequent HPV testing of 
these 5 cases revealed 3 cases with HPV 16 infection and 2 cases 
without HPV detection. In addition, we obtained tissue from 27 
of 31 PC patients for further analyses (Fig. 4). The p16-positive 
cases (n = 11) were all HPV positive and were all oropharyngeal 
of origin. Of the OPC, 12 of 23 (52.2%) were HPV positive, 
most HPV 16 (10/12; 83.3%). In 8 of 12 HPV-positive cases, we 
were informed about medication use: 6 used immunosuppressive 
therapy before HNC diagnosis (4/6 at least thiopurines).
DISCUSSION
In this nationwide study, we found that IBD patients 
with OCC have impaired survival compared with the general 
population, adjusted for TNM stage. Higher age at IBD diag-
nosis was a risk factor for OCC development in IBD and for 
PC in UC. Proximal CD localization was another risk factor for 
OCC development. Furthermore, we found that 52.2% of IBD-
associated oropharyngeal cancers were HPV positive compared 
with 30% in the general Dutch population. Immunosuppression 
did not impact the survival of patients with HNC in IBD.
We showed that 52.2% of the OPCs in IBD were 
HPV positive, which is in line with the reported prevalence 
of  HPV-positive OPCs in the (international) general pop-
ulation.34 However, the reported prevalence seems to vary 
between countries, and in recent studies on the prevalence in 
the Netherlands, lower figures (30 %) have been reported.14–16 
Differences in HPV prevalence between IBD patients with 
and without immunosuppression could not be determined 
due to the limited number of  cases. In the general population, 
patients with HPV-positive tumors have better outcomes, but 
in IBD cases, no difference in survival was observed. As OPC 
incidence is increasing, mainly due to the increased incidence 
of  HPV-positive OPCs, the potential impact of  prophylac-
tic HPV vaccines is of  interest.35, 36 This especially applies to 
immunosuppressed patients on thiopurine therapy, as reduced 
immunosurveillance may cause persisting HPV infections.
In line with colorectal cancer in IBD, OCC in IBD arises 
at a younger age (median, 60.5 vs 65.0 years; P = 0.021) and has 
an impaired prognosis.3 Furthermore, immunosuppressive ther-
apy may promote tumor progression and impair survival.6, 37 
However, we found no difference in tumor stage and overall sur-
vival in our cohort regardless of immunosuppression use. More 
specifically, thiopurines, methotrexate, and anti-TNF therapy 
did not impact risk of HNC or outcomes after treatment for 
HNC. These results must be interpreted with caution due to 
FIGURE 4. Pharyngeal cancer histopathology.
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the limited number of IBD patients with HNC. Furthermore, 
clinicians fear the negative impact of immunosuppression on 
cancer outcomes; thus immunosuppression may only be used 
in patients with a favorable risk profile. Finally, Penn38 showed 
that the risk of recurrence for (renal) transplant patients is 
highest in the first 2 years after malignancy diagnosis. Our data 
may have been influenced by wide variations in the commence-
ment of immunosuppressive therapy after cancer diagnosis.
We indentified 2 risk factors for HNC development 
in IBD: first, proximally localized disease in CD patients 
(Montreal L4, including oral cavity inflammation; OR, 1.103; 
95% CI, 1.040–1.170; P = 0.028). This may be related to upper 
gastrointestinal IBD-related inflammation. Furthermore, we 
identified older age at IBD diagnosis as a risk factor for both 
OCC and PC development. This is an interesting observation 
that is in line with other cancer types in IBD,27, 39 although our 
study does not provide an explanation for this observation.
To date, this is the largest systematically collected series 
of OCC and PC in IBD patients. However, our study also 
comes with several limitations, such as its retrospective nature. 
Especially in cases who were enrolled in early years, it was 
challenging to collect accurate and complete information. 
Therefore, we also performed a sensitivity analysis, enrolling 
only cases diagnosed with IBD after 1990. This did not show 
immunosuppressive therapy as a risk factor for OCC or PC 
development. Second, we used 3 different databases that were 
constructed in different ways to address our hypothesis. Our 
data search was retrospective, while the IBDSL and the cancer 
registry (including ECR) collect prospectively. Unfortunately, 
there is no single database available that could have answered 
our research questions sufficiently. Third, in heavy smokers, 
there is a 5- to 25-fold increased risk of cancer, in compari-
son with nonsmokers. This relation seems dose dependent. 
The relative risk to develop HNC due to alcohol also seems 
dose dependent. A  compounded effect was found for the 
combination of tobacco smoking and alcohol consumption. 
Unfortunately, these important data on tobacco and alcohol 
use were incomplete for the ECR and IBDSL. Only smoking 
data for Crohn’s disease patients were available. In univariable 
analyses, smoking emerged as a risk factor for PC, but not in 
multivariable analyses. This may be due to the limited numbers.
As HPV presence is correlated inversely with tobacco (and 
alcohol) consumption and is an important risk factor especially 
for (oro)pharyngeal cancer, this would provide important add-
itional information. Unfortunately, these data were not avail-
able for the IBDSL and ECR controls.
Finally, for several variables in the analyses, there are 
missing values. For these variables, results should be interpreted 
cautiously, as no firm conclusions can be drawn.
Some authors22, 24 have suggested oral screening for all 
IBD patients, especially those who are starting immunosup-
pression. As the incidence of HNC in IBD in general is low 
and no well-defined premalignant lesions analogous to cervical 
intraepithelial neoplasia in cervical cancer have been established 
yet, we would recommend increased awareness for HNC in IBD 
rather than active screening, especially in elderly onset IBD.
In conclusion, we found that IBD patients with OCC may 
have reduced survival compared with the general population. 
Proximal disease localization in CD is a risk factor for OCC 
development. The majority (52.2%) of IBD-associated oro-
pharyngeal cancers were HPV positive. Immunosuppression 
did not impact incidence and survival of HNC in IBD.
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APPENDIX
A: PALGA Group
E.E.C.  de Jonge (Groene Hart Ziekenhuis, Gouda), 
R.  Natte (Hagaziekenhuis, Den Haag) E.W.P. Nijhuis (Onze 
Lieve Vrouwe Gasthuis, Amsterdam), C.  Peutz-Kootstra 
(Maastricht University Medical Center, Maastricht), J.J.T.H. 
Roelofs (Amsterdam Medical Center, Amsterdam), S.M. 
Willems (University Medical Center Utrecht, Utrecht), A.P. 
Willig (Laurentius Hospital, Roermond).
B: IBD and HNC Group
A.A.  van Bodegraven (Vrije University Medical 
Centre, Amsterdam), A.C.I.T.L. Tan (Canisius Wilhelmina 
Hospital, Nijmegen), J.J. Meeuse (Hospital Rivierenland, 
Tiel), A.E.  van der Meulen–de Jong (Leiden University 
Medical Centre, Leiden), B.  Oldenburg (University Medical 
Centre Utrecht, Utrecht), B.C.A.J. Loffeld (Zuwe Hofpoort 
Hospital, Woerden), B.M. Durfeld (Hospital Group Twente, 
Almelo), C.J.  van der Woude (Erasmus Medical Centre, 
Rotterdam), D.L. Cahen (Amstelland Hospital, Amstelveen), 
G.  D’Haens (Academic Medical Centre, Amsterdam), 
D.  Janik (Ommelander Hospital Group, Delfzijl), W.G.M. 
Mares (Hospital Gelderse Vallei, Ede), L.P.L. Gilissen 
(Catharina Hospital, Eindhoven), F.L. Wolters (VieCuri, 
Venlo), G.  Dijkstra (University Medical Centre Groningen, 
Groningen), G.W. Erkelens (Gelre Hospital, Apeldoorn), 
T.J. Tang (IJsselland Hospital, Capelle aan den IJssel), 
R. Breumelhof  (Diakonessenhuis, Utrecht), H.J.T. Smalbraak 
(Lievensberg Hospital, Bergen op Zoom), J.C. Thijs (Hospital 
Bethesda, Hoogeveen), J.H. Voskuil (Hospital Tjongerschans, 
Heerenveen), J.P. Kuyvenhoven (Kennemer Gasthuis, 
Haarlem), J.  Vecht (Isala, Zwolle), M.C.M. Rijk (Amphia 
Hospital, Breda), J.M. Janssen (Onze Lieve Vrouwe Gasthuis, 
Amsterdam; Boven IJ Hospital, Amsterdam), J.T. Sarneel 
(Admiraal De Ruyter Hospital, Middelburg), J.W.M. Tjhie-
Wensing (Elkerliek Hospital, Helmond), J.Y.L. Lai (Groene 
Hart Hospital, Gouda; Langeland Hospital, Zoetermeer), 
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L.T. Vlasveld (Hospital Bronovo, Den Haag), L.E. 
Oostenbrug (Atrium Medical Centre, Heerlen), M. Gerretsen 
(Diaconessenhuis Meppel, Meppel), M.A. Van Herwaarden 
(Deventer Hospital, Deventer), N. Mahmmod (Sint Antonius, 
Nieuwegein), M.G.V.M. Russel (Medical Spectrum Twente, 
Enschede), M.J.A.L. Grubben (Sint Elisabeth Hospital, 
Tilburg), M.K. Vu (Rijnland Hospital, Leiderdorp), M.L. 
Verhulst (Máxima Medical Centre, Eindhoven), P.  Dewint 
(Van Weel – Bethesda Hospital, Dirksland; Maasstad Hospital, 
Rotterdam), P.C.F. Stokkers (Sint Lucas Andreas Hospital, 
Amsterdam), P.J. Bus (Laurentius Hospital, Roermond), P.J. 
Wismans (Havenziekenhuis, Rotterdam), P.W.E. van der Haeck 
(Refaja Hospital, Stadskanaal), R.J.L. Stuyt (Haga Hospital, 
Den Haag), R.N.M. Zeijen (Vlietland Hospital, Schiedam), 
R.P.M. Dahlmans (Sint Jans Gasthuis, Weert), S. Vandebosch 
(ZorgSaam Zeeuws-Vlaanderen, Terneuzen), T.E.H. Romkens 
(Jeroen Bosch Hospital, Den Bosch), W. Moolenaar (Medical 
Center Alkmaar, Alkmaar), W.R. ten Hove (Diaconessenhuis 
Leiden, Leiden), H. Boot (Antoni van Leeuwenhoek Hospital 
Amsterdam), K. van der Linde (Medical Center Leeuwarden, 
Leeuwarden), P.  Wahab (Rijnstate Hospital, Arnhem), 
S.Y. de Boer (Slingeland Hospital, Doetinchem), K. Thurnau 
(Ropcke Zweers Hospital, Hardenberg) W.J. Thijs (Martini 
Ziekenhuis, Groningen), D.F.G.M. Josemanders (Reinier de 
Graaf  Groep, Delft), R.L. West (Sint Franciscus Gasthuis, 
Rotterdam), M.J. Pierik (Maastricht University Medical 
Center, Maastricht), A.C.T.M. Depla (Slotervaart Hospital, 
Amsterdam), E.T.P. Keulen (Orbis Medical Center, Sittard), 
W.A.  de Boer (Bernhoven Hospital, Uden), A.H.J. Naber 
(Tergooi Hospital, Hilversum), J.R. Vermeijden (Meander 
Medical Center, Amersfoort), R.C. Mallant-Hent (Flevo 
Hospital, Almere), R.  Beukers (Albert Schweitzer Hospital, 
Dordrecht), P.C.J. Ter Borg (Ikazia Hospital, Rotterdam), 
E.C.R. Halet (Franciscus Hospital, Roosendaal), K.F. Bruin 
(Twee Steden Hospital, Tilburg), R.K. Linskens (Sint Anna 
Hospital, Geldrop), W.  Bruins Slot (Spaarne Hospital, 
Hoofddorp).
SUPPLEMENTARY DATA
Supplementary data are available at Inflammatory Bowel 
Diseases online.
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